The predictive value of urinary kidney injury molecular 1 for the diagnosis of contrast-induced acute kidney injury after cardiac catheterization: a meta-analysis by Li, Q. et al.
Research Article
The Predictive Value of Urinary Kidney InjuryMolecular 1 for the
Diagnosis of Contrast-Induced Acute Kidney Injury after Cardiac
Catheterization: A Meta-Analysis
Qing Li,1,2 Yimin Huang,3 Weifeng Shang,4 Ying Zhang,1 Yanyan Liu ,1 and Gang Xu 1
1Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,
Wuhan 430030, Hubei Province, China
2Department of Nephrology, Medical Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany
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Background. Urinary kidney injury molecule 1 (uKIM-1) is a proximal tubular injury biomarker for predicting acute kidney injury
(AKI); its prognostic value varies depending on the clinical and population characteristics. However, the predictive value of
uKIM-1 for diagnosis of contrast-induced acute kidney injury (CI-AKI) remains unclear. Method. Medline, Embase, Clin-
icalTrials.gov, Cochrane Library database, and the China National Knowledge Infrastructure (CNKI) were used to identify
relevant studies from their inception to November 31, 2019. Studies that met the inclusion criteria were included. Relevant data
were extracted to obtain pooled sensitivity (SEN) and specificity (SPE), summary receiver operating characteristic curve (ROC),
and area under the ROC (AUC or AUROC). A bivariate mixed-effects regression model was used for data analysis. Results. A total
of 946 patients from 8 eligible studies were included. Across all the studies, the diagnostic odds ratio (DOR) for uKIM-1 level to
predict CI-AKI was 19 (95% CI 10–39), with SEN and SPE of 0.84 and 0.78, respectively. 0e AUROC for uKIM-1 in predicting
CI-AKI was 0.88 (95% CI 0.85–0.90). 0ere was a substantial heterogeneity across the studies (I2 was 37.73% for the summary
sensitivity and 69.31% for the summary specificity). Conclusion. Urinary KIM-1 has a high predictive value for diagnosis of CI-
AKI in patients who have undergone cardiac catheterization.
1. Introduction
Contrast-induced acute kidney injury (CI-AKI) is a com-
mon and serious complication after cardiac catheterization
(CC), percutaneous coronary intervention (PCI), and cor-
onary angiography (CAG). It accounts for 12% of all hos-
pital-acquired kidney failure and increases the length of
hospitalization, a situation that is worsening with increasing
numbers of patients with comorbidities, including those
requiring cardiovascular interventional procedures [1].
Unfortunately, current preventive methods for CI-AKI are
limited and often ineffective [2]. 0us, the early and effective
diagnosis of CI-AKI is important. Currently, the
concentration of serum creatinine (sCr) is the most com-
monly accepted clinical standard for diagnosis of CI-AKI
and it has several limitations. For example, sCR is affected by
many factors (e.g., age, sex, race, weight, and drugs) [3].
Moreover, it takes over 24 to 48 hours to diagnose CI-AKI
using sCr, which makes it too late for intervention [4]. 0us,
sCr is believed to be inadequate for the diagnosis of CI-AKI,
and there is an urgent need for biomarkers that can detect
CI-AKI sooner and more accurately.
Kidney injury molecule 1 (KIM-1) is a phosphati-
dylserine receptor that is expressed in epithelial cells. It
enables epithelial cells to recognize and phagocytose dead
cells that are present in the stressed kidney [5]. KIM-1 is
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undetectable in the urine of normal subjects [6]. However,
following renal tubular injury, KIM-1 is upregulated and
delivered into the extracellular space and the urine, making
it possible to detect renal damage [6, 7]. Previous reports
have demonstrated that KIM-1 is an excellent predictor of
proximal tubular injury compared with sCr in rats [7].
Several human studies have also shown that urinary KIM-1
(uKIM-1) can be detected well before the increase of sCr,
thus making it a sensitive and specific early biomarker of CI-
AKI [8–10]. Recently, reviews have shown that uKIM-1 is a
promising biomarker for the diagnosis of acute kidney in-
jury (AKI) [1, 11]. However, the predicative value of uKIM-1
for CI-AKI after percutaneous coronary intervention (PCI)
or coronary angiography (CAG) still remains to be estab-
lished. 0is meta-analysis was conducted to determine the
predictive ability of uKIM-1 for the diagnosis of CI-AKI
following PCI or CAG based on research evidence currently
available.
2. Methods
2.1. Search Strategy. 0is meta-analysis was performed
according to the guideline of PRISMA statement [12].
Relevant articles were identified through a systematic search
of PubMed, Medline, Embase, Cochrane Library, Clinical-
Trials.gov, and the China National Knowledge Infrastructure
(CNKI) databases from their inception to November 31,
2019, with no language restriction. 0e following search
terms were used: (KIM1OR KIM-1 OR kidney injury
molecule 1) AND (contrast OR radio contrast OR contrast
media OR contrast medium [CM] OR radio-contrast media
OR radio contrast medium OR contrast agent] AND (acute
kidney injury OR AKI OR acute kidney failure OR renal
failure) AND (coronary angiography OR percutaneous
coronary interventions OR cardiac catheterization). Refer-
ences of relevant studies were searched manually to identify
eligible studies. In addition, abstracts were included in this
meta-analysis if they contained complete results sections.
0e search was performed by two investigators (QL and
YH).
2.2. StudySelection. Studies were assessed and selected based
on titles and abstracts by two independent reviewers; con-
flicts were resolved by a third reviewer (YL). 0e inclusion
criteria were as follows:
(1) uKIM-1 was used as a biomarker to diagnose CI-AKI
after PCI or CAG.
(2) 0e study should be observational.
(3) uKIM-1 concentration values for true-positive, false-
negative, false-positive, and true-negative were
provided or could be calculated to predict CI-AKI.
0e exclusion criteria were as follows:
(1) Review articles or duplicate papers
(2) Animal or in vitro based studies
(3) Studies that did not provide the diagnostic accuracy
of uKIM-1
2.3. Data Extraction and Study Quality Assessment. After a
detailed full-text review of each study, data was extracted
from the retained studies by two independent reviewers (QL
and YH). Disagreements were resolved by discussion and
assessed by a third reviewer (YL) until a consensus was
reached. 0e following data were extracted from the in-
cluded studies for analysis: first author, year of publication,
original country, sample size, study design, incidence of CI-
AKI, inclusion renal criteria, patient characteristics (age, sex,
baseline serum creatinine, and the proportion of patients
with hypertension and diabetes mellitus), definition of CI-
AKI, and CM (contrast media) type. Information about
biological material, measurement assay, and time of uKIM-1
management was also collected. In addition, sensitivity and
specificity from the cutoff value of the uKIM-1 level pre-
dicting CI-AKI (obtained by receiver operating character-
istic (ROC) analysis and the area under the curve (AUC) of
ROC) were extracted from the studies.
0e methodological quality of each included study was
assessed by two independent reviewers (QL and YH) who
used the Quality Assessment of Diagnostic Accuracy
Studies-2 (QUADAS-2) tool [12].
2.4. Statistical Analysis. Statistical analyses were performed
using STATA version 14.0 (Stata Corp, College Station, TX),
notably with the “midas” commands [13]. An exact binomial
rendition of the bivariate mixed-effects regression model
that was developed by von Houwelingen et al. [14] for meta-
analysis of treatment trials and modified for diagnostic test
data using an approximate normal within study model was
used [15]. 0e bivariate mixed-effects model fits a 2-level
model, with independent binomial distributions for the true
positives and true negatives conditional on the sensitivity
and specificity in each study, and a bivariate normal model
for the logit transformations of sensitivity and specificity
between studies [13]. Based on this model, the pooled
sensitivity (SEN), pooled specificity (SPE), positive likeli-
hood ratio, negative likelihood ratio, and diagnostic odds
ratio (DOR) with their 95% CIs were obtained. We also
constructed hierarchical summary ROC curves to plot
sensitivity versus specificity and calculated the AUC [16].
0e degree of the heterogeneity, which indicates the vari-
ation of included studies, was assessed using the I2 statistic
[15]. I2 describes the percentage of total variation across
studies that is attributable to the heterogeneity rather than to
chance. 0e value of I2 lies between 0% and 100%, a value of
0% indicates no observed heterogeneity, and values greater
than 50% may be considered substantial heterogeneity [13].
In addition, we conducted a subgroup analysis according to
the detection time, sample size, and presence of chronic
kidney disease. Publication bias was evaluated using Deek’s
effective sample size funnel plot.
3. Results
3.1. Study Selection. 0e study selection process is shown in
Figure 1. A total of 1116 publications from different data-
bases were retrieved upon initial search. Of those, 657
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articles were excluded due to duplication. 0e remaining
studies were screened by title and/or abstract; 441 of them
were removed because they were reviews, animal research,
or conference abstracts. Of the remaining 18 studies, 9 were
excluded due to missing essential data (e.g., SEN, SPE, and
diagnostic criteria used). In addition, one article [17] was
found during the manual review of the references of a review
article [1] and included in this meta-analysis. In summary, 9
original studies [8–10, 17–22] were included in this meta-
analysis.
3.2. Study Characteristics. All studies were single-center
trials that had their findings published between 2013 and
2017. Of the included studies, 7 were published in English
[8–10, 17–19, 22], and 2 were published in Chinese [20, 21].
0e 9 studies included a total of 946 adult patients from 5
countries who underwent PCI or GAC, and 144 were
diagnosed as CI-AKI. Among these studies, 8 included
patients with normal sCr levels and 1 [10] included CKD
patients. Patients treated with dialysis or who used renal
toxic drugs were excluded from all studies. However, the
definition of CI-AKI differed among the studies. Six of the
studies used a traditional definition for CI-AKI (increase in
SCr≥ 0.5mg/dL or≥ 25% within 48–72 hours after contrast
exposure) [4], while three studies did not [8, 17, 19]. 0e
characteristics of all the individual studies are listed in
Table 1.
3.3. Methodological Quality of Included Studies. 0e meth-
odological quality assessment for the studies included in this
meta-analysis is shown in Table S1. 0e overall quality of the
eligible studies was not robust. Most studies showed low risk
in the domain of patient selection, while three studies
[8, 18, 20] that did not avoid a case-control design showed
1116 articles are identified in initial research
449 via Medline
653 via Embase
5 via Cochrane library
7 via CKNI
1 via ClinicalTrail.gov
1 from references of a review
657 excluded (duplicate) 





18 searched full text articles
9 excluded
Incomplete data extraction
9 studies included for meta-analysis
Figure 1: Flow diagram for the review process and outcomes of inclusion and exclusion.
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high risk. An unclear risk was shown in the domain of index
test since most of the studies did not indicate if a threshold
was used. An unclear risk was also shown in the domain of
risk of bias because information about whether reference
standard results were interpreted without knowledge of the
results of the index test was not provided in most studies.
0ere was high risk in the domain of flow and timing be-
cause two studies [10, 20] did not include all the patients in
the analysis. All the studies were regarded to be of low risk
for concerns regarding applicability.
3.4.Result of Individual Studies. 0eperformance of uKIM-1
concentrations for predicting CI-AKI has been summarized
in Table 2. Urinary KIM-1 levels were measured in all of the
studies. Enzyme-linked immunosorbent assay (ELISA) was
used in all of the studies to evaluate the level of uKIM-1. 0e
time of the uKIM-1 test ranged from 6 to 24 hours after PCI
or GAC.0e cutoff value of the uKIM-1 level used to predict
CI-AKI varied from 0.048 to 6.33 ng/ml, and one study even
set the cutoff value as 3 times of the baseline uKIM-1.
Moreover, the AUC of uKIM-1 for predicting CI-AKI
ranged from 0.713 to 0.95.
3.5. Meta-Analysis. As shown in Figure 2, the pooled sen-
sitivity and specificity of all studies was 0.84 (95% CI
0.76–0.90) and 0.78 (95% CI 0.71–0.84), respectively. I2 was
37.73 for the summary sensitivity and 69.31 for the summary
specificity, suggesting a substantial heterogeneity in the
sample of studies. 0e area under the receiver operating
characteristic curve (AUROC) was 0.88 (95% CI 0.84–0.90).
0e SROC graph with the 95% confidence region and the
95% prediction region are shown in Figure 3.
A subgroup analysis was performed to explore potential
sources of heterogeneity among studies. As shown in Table 3,
the diagnostic accuracy of uKIM-1 was higher in test time of
<24 hour group than test time at 24 hour group. However,
the opposite findings were found in the subgroups with CKD
and large sample sizes.
0e result of the Deek’s funnel plot asymmetry test with
a superimposed regression line is shown in Figure 4. 0e P
value for the slope coefficient was 0.12, indicating nonsig-
nificant asymmetry. 0is result indicates no potential
publication bias among studies.
4. Discussion
In recent years, the gold standard for AKI diagnosis, the
concentration of serum creatinine, has showed many lim-
itations. 0us, several new biomarkers for early detection of
AKI have been studied. Among them, the most promising
are neutrophil gelatinase-associated lipocalin (NGAL) and
kidney injury molecule 1 (KIM-1).
KIM-1 is a phosphatidylserine receptor and expressed in
epithelial cells. It can recognize and phagocytose dead cells
that are present in the stressed kidney [5]. In normal sit-
uations, KIM-1 is undetectable in urine. But when the
proximal tubule suffers from ischemic or toxic injury, the
ectodomain of KIM-1 is shed into the urine of humans [6, 7].
As a result, it is possible to use urinary KIM-1 (uKIM-1) to
predict tubular injury and AKI.
A number of clinical studies have reported the excellent
diagnostic value of uKIM-1 level for AKI caused by different
reasons and in different populations [23–25]. 0e findings
from a meta-analysis evaluating the predictive value of
uKIM-1 in the setting of AKI, which included 2979 patients
from 11 studies, suggest it is an efficacious diagnostic marker
for AKI [11]. However, AKI caused by use of imaging
contrast has not been systematically assessed to date. 0us,
we performed a systematic and comprehensive review to
investigate the diagnostic value of uKIM-1 for early de-
tection of CI-AKI in patients who undergo PCI or CAG. To
our knowledge, this is the first meta-analysis performed to
evaluate the ability of uKIM-1 to predict CI-AKI.
Although we tried our best to search for all the eligible
studies, there were only 9 that met our inclusion criteria and
were included in the meta-analysis. Fortunately, these 9
studies showed a considerate homogeneity, indicating that
the pooled results in this meta-analysis were reliable and
stable.
In our study, SEN, SPE, and AUC were used for indi-
cating the performance of uKIM-1 for CI-AKI prediction; all
the studies showed that uKIM-1 was a good predictor. 0e
AUC values were above 0.70 for all studies (in fact, two
studies reported an AUC >0.90(18, 22)). Moreover, the
pooled AUC (0.88, 95% CI 0.85–0.90) also indicates a
considerable value in using uKIM-1 for the diagnosis of CI-
AKI. Ho et al. constructed a meta-analysis of using uKIM-1
for diagnosis of AKI associated with cardiac surgery [26]. In
this meta-analysis, the AUC of uKIM-1 for intraoperative
and postoperative AKI were 0.68 (0.58–0.78) and 0.72
(0.69–0.84), respectively. 0ere was also a meta-analysis
carried out by Wang et al. that assessed the predictive value
of NGAL for CI-AKI and showed an AUC of 0.93 [27]. In
comparison with the aforementioned findings, we ascer-
tained that uKIM-1 was much more effective for the diag-
nosis of CI-AKI than for cardiac surgery associated AKI but
less powerful than NGAL for predicting CI-AKI.
Urinary KIM-1 was reported to be influenced by de-
tection time. In a cohort of 103 adults undergoing cardio-
pulmonary bypass (CPB), the uKIM-1 levels increased by
approximately 40% at 2 hours postoperatively and by more
than 100% at the 24-hour time point [28]. In a nested case-
control study consisting of cardiac catheterization patients,
uKIM-1 increased 6 hours after contrast from the baseline
and peaked at 24 hours, suggesting it may perform well in
the relatively late time period (rather than at 6 hours) after
AKI (19). We also found that 24-hour postcontrast exposure
time was the best detecting point for uKIM-1. We stratified
the included studies based on test times, 24 hours (detected
uKIM-1 24 hours after contrast exposure), and <24 hours
group (detected uKIM-1 24 hours before contrast exposure)
and noticed that the values of AUC in 24 hour group were
higher than those of the under 24 hours group. One of these
studies detected uKIM-1 at both 6 hours and 24 hours after
contrast and reported an AUC of 0.74 (95% CI 0.49–0.91,
P � 0.0064) and 0.85 (95% CI 0.72–0.95, p0.002), respec-
tively. Another study [18] also illustrated that it is better to
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detect KIM-1 at 24 hours after contrast exposure. However, a
study by Han et al. [29] showed that uKIM-1 levels did not
rise significantly in patients of contrast-induced nephrop-
athy.0ese mixed findings might be explained by differences
in the renal inclusion criteria, inconsistent timing of urinary
collections, and variable measurement methods.
Most of the included studies did not include patients
with CKD, except for the study conducted by Wang et al.
[10]. 0e results of the sensitivity analysis show that ex-
clusion of CKD increased the stability of sensitivity. 0is
indicates that the accuracy of uKIM-1 for predicting CI-AKI
differs between patients with and without CKD. AKI that
happened on CKD patients is known to be severe and
different to recover [30]. 0e pathophysiological changes of
CKD, such as the activation of TGF-β, p53, and HIF
pathways in kidney and CKD related chronic inflammation
Table 2: Performance of KIM-1 for CIN or CI-AKI diagnosis in the meta-analysis.







1 Wybraniec et al.[22] 7 15 2 71 95 6h 0.0081 NR 0.778 0.824 >0.425 Urine ELISA
2 Akdeniz et al. [8] 24 5 8 15 52 6 0.797 0.677–0.917 75 75 3.66 Urine ELISA
3 Li et al. [9] 14 18 5 108 169 24 0.854 0.782–0.929 73.7 85.7 6.327755 Urine ELISA
4 Luo et al. [18] 10 4 2 26 42 24 0.85 0.72–0.95 83 87 0.74 Urine ELISA
5 Torregrosa et al.[19] 14 45 6 79 144 12 0.713 0.551–0.876 71.6 64 1.73 Urine ELISA
6 Wang and Pu[20] 12 8 2 20 42 24 0.839 0.095–0.948 85.7 71.4 4.495 Urine ELISA
7 Wang [21] 17 60 3 180 260 12 0.903 0.802–0.100 85 75 0.0478425 Urine ELISA
8 Wang et al. [10] 59 1 3 3 66 12 0.742 NR 95.2 75 3
∗KIM-1
baseline Urine ELISA
9 Vijayasimhaet al. [17] 11 17 1 71 100 24 0.95 NR 89 81 4.5 Urine ELISA
Sensitivity (95% CI)
Q = 12.85, df = 8.00, p = 0.12
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Figure 2: Forrest plots of the sensitivity and specificity of each individual study, summary sensitivity and specificity, and I2 statistic for
heterogeneity.
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and vascular dysfunction, might contribute to the severe
AKI progress [30]. On the contrary, some clinical studies
found that KIM-1 did not provide robust prognostic in-
formation on the loss or renal function in CKD population
[31, 32]. Since the sample size was small in Wang et al. [10]
research, studies with a larger sample size are needed to
clarify this problem.
Recently, similar meta-analysis studies were done on the
predictive value of KIM-1 in predicting AKI in different
populations. However, the diagnostic value of KIM-1 varied.
In a meta-analysis included general population, KIM-1 was
found to be a promising biomarker for AKI prediction with
an AUC of 0.86 [11]. In another study which only enrolled
children, KIM-1 (AUC� 0.69) is not recommended for AKI
diagnosis [33]. 0ose conflicted conclusions show that the
diagnostic power of KIM-1might not be consistent in people
of different ages. Further, KIM-1 only showed modest
discrimination in diagnosing AKI in cardiac surgery patients
[26] and showed stronger diagnostic power in our studies
with patients received cardiac catherization treatment, since
contrast is the main cause of AKI after cardiac catherization
[34], while ischemia contributes to AKI after cardiac surgery
in most cases [35]. 0e difference in pathophysiological
mechanisms in these two conditions might lead to the
discrepancy in KIM-1 diagnostic value on AKI.
5. Limitations
Limitations of this meta-analysis include the small number
of studies included. Also, it was hard to assess influence of
detecting time, as most studies detected uKIM-1 at different




















SENS = 0.84 [0.76 − 0.90]
SPEC = 0.78 [0.72 − 0.84]
SROC curve
AUC = 0.88 [0.85 − 0.90]
95% confidence contour
95% prediction contour
Figure 3: Summary receiver operating characteristic (SROC) graph with 95% confidence region and 95% prediction region for the diagnosis
value of CI-AKI by KIM-1.
Table 3: Subgroup analysis.
Subgroup N Sensitivity Specificity DOR AUC
Test time< 24 h
<24 h 5 0.84(0.70, 0.93) 0.72 (0.64, 0.79) 15 (5, 42) 0.81 (0.77–0.84)
24 h 4 0.83(0.70, 0.91) 0.83 (0.77, 0.87) 23 (11, 49) 0.89 (0.86–0.91)
ckd
No 8 0.79 (0.71,0.86) 0.77 (0.70,0.83) 13 (7,24) 0.83 (0.80–0.86)
Yes 1 95.2 75 0.742
Large sample size
≤100 4 0.79 (0.68,0.87) 0.77 (0.68,0.84) 13 (6,29) 0.84 (0.80–0.87)
>100 5 0.87 (0.75,0.94) 0.78 (0.67,0.86) 24 (9,69) 0.80 (0.76–0.83)
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studies tested more than one biomarker; however, the details
for the combined diagnosis of uKIM-1 and other biomarkers
were not reported. Moreover, patients with different renal
function and age were not accounted for (or controlled for)
in most of the study designs.
6. Conclusion
0e findings from this meta-analysis demonstrate that
uKIM-1 is a relatively good biomarker for prediction CI-
AKI in patients who undergo PCI or CAG. 0e optimal
detection time is 24 hours after contrast exposure, suggesting
that uKIM-1 can predict CI-AKI at an earlier time than sCr.
Clinical studies with large sample sizes are needed to further
explore the diagnostic ability and prognostic value of uKIM-
1 in different populations (e.g., different age, renal function,
and comorbidities).
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[31] N. A. Bhavsar, A. Köttgen, J. Coresh, and B. C. Astor,
“Neutrophil gelatinase-associated lipocalin (NGAL) and
kidney injury molecule 1 (KIM-1) as predictors of incident
CKD stage 3: the atherosclerosis risk in communities (ARIC)
study,” American Journal of Kidney Diseases, vol. 60, no. 2,
pp. 233–240, 2012.
[32] L. M. Black, J. M. Lever, A. M. Traylor et al., “Divergent effects
of AKI to CKD models on inflammation and fibrosis,”
American Journal of Physiology-Renal Physiology, vol. 315,
no. 4, pp. F1107–F1118, 2018.
[33] M. Fazel, A. Sarveazad, K. Mohamed Ali, M. Yousefifard, and
M. Hosseini, “Accuracy of urine kidney injury molecule-1 in
predicting acute kidney injury in children; a systematic review
and meta-analysis,” Archives of Academic Emergency Medi-
cine, vol. 8, no. 1, p. e44, 2020.
[34] M. Fähling, E. Seeliger, A. Patzak, and P. B. Persson, “Un-
derstanding and preventing contrast-induced acute kidney
injury,” Nature Reviews Nephrology, vol. 13, no. 3, pp. 169–
180, 2017.
[35] Y. Wang and R. Bellomo, “Cardiac surgery-associated acute
kidney injury: risk factors, pathophysiology and treatment,”
Nature Reviews Nephrology, vol. 13, no. 11, pp. 697–711, 2017.
Journal of Interventional Cardiology 9
